

***Trust Logo***

**<GLH region name>**

**NHS Genomic Laboratory Hub**

|  |  |  |
| --- | --- | --- |
| ***Head of Department****Name* |  | *Local Genetics Service**Local Trust**Address**Address**Post Code**Web site address* |
| General Enquiries: *telephone contact*Email: *generic email address* |
|  |

**GENOMIC LABORATORY REPORT**

|  |  |  |
| --- | --- | --- |
| Dr xxx | **Patient Name:** | **John DOE** |
| Consultant  | Gender: | Male |
| <<Hospital address>> | Date of Birth: | 14 Jan 1968 |
| NHS No: | 123 456 7890 |
| Hospital No: | NK |
| Your ref: | GC12345 |

**Reason for testing**

Predictive testing. <<Referral reason>>

|  |
| --- |
| **Result summary** |
| **At elevated risk of *BRCA2*-associated cancers** |

**Result**

This individual is heterozygous for the familial germline xxlikelyxx pathogenic *BRCA2* missense/truncating/splice variant (details below). Heterozygous *BRCA2* pathogenic variants cause cancer susceptibility (OMIM: 600185), particularly breast and ovarian cancer in females.

**Implications**

Each of his offspring would be at 50% risk of inheriting the pathogenic variant. His descendants and other relatives are at increased risk of developing *BRCA2*-associated cancers.

**Recommended action**

This individual is at increased risk of developing *BRCA2*-associated cancers and should be managed appropriately. We recommend referral to Clinical Genetics where specific risk figures for males can be discussed, and predictive / diagnostic testing for this variant in his relatives can be arranged.

Date issued: <AUTHORISEDDATE> Authoriser: Clinical Scientist

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**TECHNICAL INFORMATION**

**Familial variant details**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | Zygosity | HGVS description | Location: GRCh37 (hg19) | \*Classification in proband |
| *BRCA2* | Heterozygous | NM\_000059.3: c.xxT>C p.(Xxx) | Chr13(GRCh37):g.xxxxxxA>G | Likely pathogenic |

**Test methodology**

1. METHODOLOGY e.g. Genomic DNA Sanger sequencing with direct chromatogram check >95% sensitivity
2. Only relevant results are shown; full details of methods and results, including benign/likely benign variants and variants of uncertain clinical significance with very limited evidence for pathogenicity are stored on file and are available on request.
3. Variant classification according to the American College of Medical Genetics and Genomics (ACMG)1 and Association for Clinical Genomic Science (ACGS) 2020 guidelines2 and Cancer Variant Interpretation Group-UK consensus specification for Cancer Susceptibility Genes3 (<https://www.cangene-canvaruk.org/canvig-uk>)

1Richards *et al.* (2015) Genetics in Medicine 17:405-24. (PMID 25741868)

2[www.acgs.uk.com/quality/best-practice-guidelines](file:///%5C%5C3PA0-DATA-SERVER%5CDATA%5CSCH%5CGEN%5CDNA%5CSHARED%5CDNA%5CHereditary%20cancers%5CService%20Management%5CHC%20report%20examples%5CCanVIG%20report%20templates%202020%5Cwww.acgs.uk.com%5Cquality%5Cbest-practice-guidelines)

3 Garrett et al (2020) J Med Genet (PMID: 32170000)

**Sample details**

|  |  |  |  |
| --- | --- | --- | --- |
| Your lab ref: | 122001180 |  |  |
| Sample ID: | 1234567 | Sample collected: | 05 Jun 2020 |
| Sample type: | DNA from peripheral blood | Sample received: | 05 Jun 2020 |
| Dr xxx | **Patient Name:** | **John DOE** |
| Consultant  | Gender: | Male |
| <<Hospital address>> | Date of Birth: | 14 Jan 1968 |
| NHS No: | 123 456 7890 |
| Hospital No: | NK |
| Your ref: | GC12345 |

**Appendix 1: Variant classification**

**Variant details**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | Zygosity | HGVS description | Location: GRCh37 (hg19) | \*Classification |
| *BRCA2* | Heterozygous  | NM\_000059.3:c.xxxT>G | Chr13(GRCh37):g.xxxxxxA>C | Likely pathogenic |
| Gene-Disease Association | Hereditary cancer susceptibility OMIM 600185 |
| Inheritance | Autosomal Dominant  |
| **Evidence for variant classification using ACMG/AMP guidelines\***:  | Exponent (Bayesian) score^ |
| PS3\_strPM2\_modPS4\_modPP3\_sup | LOF on functional assay xxx et al 2018 (PMID: xxx) Not on gnomad [<weblink>](https://gnomad.broadinstitute.org/variant/17-41249298-A-C)XXX et al 2003 (PMID:XXX); XXX et al 2016 (PMID:xxx); LOVD/BRCAshare x6Revel score >0.7 | 42 |
| 2 |
| 1 |
| Total: 9 |

^Evidence point ranges: VUS: 0-5 (10-90% posterior probability pathogenicity); Likely pathogenic: 6-9 (90-99% posterior probability); Pathogenic: >10 (>99% posterior probability). Points awarded per evidence weighting: sup (supporting) = 1, mod (moderate) = 2, str (strong) = 4, vstr (very strong) = 8 (Tavtigian et al 2020 PMID: [32720330](https://pubmed.ncbi.nlm.nih.gov/32720330/); Garrett et al 2020 PMID: [33208383](https://pubmed.ncbi.nlm.nih.gov/33208383/); [ACGS 2020 variant guidelines](http://www.acgs.uk.com/quality/best-practice-guidelines))

\*Variant classification according to the American College of Medical Genetics and Genomics (ACMG)1 and Association for Clinical Genomic Science (ACGS) 2020 guidelines2 and Cancer Variant Interpretation Group-UK consensus specification for Cancer Susceptibility Genes3 (<https://www.cangene-canvaruk.org/canvig-uk>)

1Richards *et al.* (2015) Genetics in Medicine 17:405-24. (PMID: [25741868](https://pubmed.ncbi.nlm.nih.gov/25741868/))

2 [www.acgs.uk.com/quality/best-practice-guidelines](file:///C%3A%5CUsers%5Cdnamd%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5CF1S86UOM%5Cwww.acgs.uk.com%5Cquality%5Cbest-practice-guidelines)

3 Garrett et al (2020) J Med Genet (PMID: [32170000](https://pubmed.ncbi.nlm.nih.gov/32170000/))